NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE) announced the appointment of Chris Boshoff, M.D., Ph.D., as its new Chief Scientific Officer and President of Research & Development, effective January 1 ...
Pfizer Inc. named oncology research head Chris Boshoff as the drug company’s chief scientific officer while it works to fend off activist criticism that its pipeline is underwhelming. Boshoff ...
which said Pfizer had overspent on big acquisitions as well as run disappointing internal research and development operations. Under CEO Albert Bourla, the New York-based drugmaker poured money ...
Pfizer PFE-1.45%decrease; red down pointing triangle elevated the executive in charge of its cancer-drugs business to oversee all of the drugmaker’s research and development, a crucial move at a ...
The appointment of Boshoff as head of R&D also comes as Pfizer fends off activist investor Starboard Value, which has accused the company of running poor research and development operations ...
Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year.
The stock was down 1.3% at 3:21 p.m. in New York. Pfizer’s shares have shed more than half their value since peaking in December 2021. Since then, Bourla has embarked on a $70 billion string of ...
NEW YORK: Pfizer Inc says annual revenue from its mRNA vaccine portfolio could reach US$10bil (RM44.3bil) to US$15bil (RM66.4bil) by 2030, alleviating fears of a sharp hit to its top line from an ...
Image Credit: AFP New York: Pfizer reported earnings that topped expectations Tuesday following an uptick in sales of a Covid-19 therapeutic and gains from other products. The big drugmaker has in ...